



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Evan C. Unger et al.

Serial No.: **09/218,660**

Group Art Unit: **1619**


Filed: **December 22, 1998**

Examiner: **S. Sharareh**

For: **NOVEL TARGETED COMPOSITIONS
FOR DIAGNOSTIC AND THERAPEUTIC USE**

I, **S. Maurice Valla**, Registration No. **43,966**, certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On January 15, 2001


S. Maurice Valla, Registration No. **43,966**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

**RESPONSE UNDER 37 C.F.R. § 1.111
TO OFFICE ACTION MAILED JULY 18, 2000**

In response to the Office Action mailed July 18, 2000, please amend the application, without prejudice, as follows.

In the Claims

100. (Amended) A formulation for therapeutic or diagnostic use comprising, in combination with a bioactive agent, lipid[, protein or polymer] vesicles encapsulating a

RECEIVED
JAN 23 2001
TECH CENTER 1600/2900

RECEIVED
JUL 25 2001
TECH CENTER 1600/2900